BioSpace News Archive

China continues to be a hotbed of investment for U.S. pharmaceutical and biotech companies. Last week BioSpace reported that China expects to see exponential industry growth by 2022 and today Eli Lilly and Company added to that growth through a partnership with China’s National Center for Cardiovascular Diseases.

On April 16, Celldex Therapeutics reported that its Phase IIb trial of glembatumumab vedotin (glemba) failed in a trial of metastatic triple-negative breast cancer. Now the company has filed with the U.S. Securities and Exchange Commission (SEC) that it is cutting about 20 percent of staff.

The biopharma industry is starting to leverage mobile apps and other digital technologies to improve access to clinical trials. Novartis launched FocalView, an app for ophthalmic patients involved in eye-related clinical trials.

Corvidia Therapeutics, headquartered in Waltham, Massachusetts, closed on a Series B funding round worth $60 million.

In its first-quarter earnings report, Thousand Oaks, California-based Amgen cited total revenue for the quarter of $5.6 billion, up 2 percent compared to the first quarter of 2017. But the quarter’s earnings were driven by double-digit growth for new and recently launched products.

With $37 million in its pocket a new player has emerged to develop treatments for rare diseases.

The U.S. Supreme Court delivered a blow to the nation’s pharmaceutical industry when it upheld the constitutionality of Inter Partes Review (IPR).

The chief executive officer and two associates of Cambridge, Massachusetts-based PixarBio were arrested yesterday and charged with securities fraud.

Despite strong sales of shingles vaccine Shingrix, GlaxoSmithKline reported its sales and earnings fell 2 percent in the first quarter of the year, largely due to challenges in respiratory sales as well as significant currency impact.

ADC Therapeutics has pulled the plug on its Phase I drug candidate that targets solid tumors with HER2 expression.